Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer
Status:
Recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
The study assesses the efficacy of neoadjuvant treatment with pyrotinib and trastuzumab with
chemotherapy, mainly pathological complete response (pCR) rates in the breast and axilla.
And also assesses side effects, event-free survival (EFS), disease-free survival (DFS),
distant disease-free survival (DDFS), and objective response rates (ORR).
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University